Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Wroblewski, M ^a   Bauer, R ^a   Cubas Cordova M ^a   Udonta, F ^a   Ben Batalla, I ^a   Legler, K ^a,b   Hauser, C ^b   Egberts, J ^b   Janning, M ^a   Velthaus, J ^a   Schulze, C ^a   Pantel, K ^a   Bokemeyer, C ^a   Loges, S ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIASTHMATIC AGENT; CROMOGLYCATE DISODIUM; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME; GZMB PROTEIN, HUMAN; GZMB PROTEIN, MOUSE; KDR PROTEIN, HUMAN; KDR PROTEIN, MOUSE; LAMININ; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN; VITRONECTIN;

ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; MAST CELL; METABOLISM; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); SECRETION (PROCESS); TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-ASTHMATIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CROMOLYN SODIUM; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GRANZYMES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; LAMININ; MAST CELLS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VITRONECTIN;

EID: 85027533382     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-00327-8     Document Type: Article

References (70)

1. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (2011).
2. Stapor, P., Wang, X., Goveia, J., Moens, S. & Carmeliet, P. Angiogenesis revisited - role and therapeutic potential of targeting endothelial metabolism. J. Cell Sci. 127, 4331-4341 (2014).
3. Welti, J., Loges, S., Dimmeler, S. & Carmeliet, P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Invest. 123, 3190-3200 (2013).
4. Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410 (2003).
5. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049 (2008).
6. Mackey, J. R. et al. Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat. Rev. 38, 673-688 (2012).
7. van Beijnum, J. R., Nowak-Sliwinska, P., Huijbers, E. J., Thijssen, V. L. & Griffioen, A. W. The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol. Rev. 67, 441-461 (2015).
8. Vasudev, N. S. & Reynolds, A. R. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17, 471-494 (2014).
9. Jonasch, E. et al. Chromosome 14q imbalances and pathways associated with resistance to antiangiogenic therapy in clear cell renal cell carcinoma. J. Clin. Oncol. 29, 339 (2011).
10. Dey, N., De, P. & Brian, L. J. Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors. Am. J. Transl. Res. 7, 1675-1698 (2015).
11. von Minckwitz, G. et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N. Engl. J. Med. 366, 299-309 (2012).
12. von Minckwitz, G. et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)dagger. Ann. Oncol. 25, 2363-2372 (2014).
13. Ben-Batalla, I. et al. Cyclooxygenase-2 blockade can improve efficacy of VEGFtargeting drugs. Oncotarget 6, 6341-6358 (2015).
14. Jain, R. K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer. Cell 26, 605-622 (2014).
15. Loges, S., Schmidt, T. & Carmeliet, P. Mechanisms of resistance to antiangiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 1, 12-25 (2010).
16. Kessler, D. A., Langer, R. S., Pless, N. A. & Folkman, J. Mast cells and tumor angiogenesis. Int. J. Cancer 18, 703-709 (1976).
17. Pittoni, P. et al. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res. 71, 5987-5997 (2011).
18. Ribatti, D. et al. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur. J. Clin. Invest. 33, 420-425 (2003).
19. Soucek, L. et al. Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma. Neoplasia 13, 1093-1100 (2011).
20. Blair, R. J. et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J. Clin. Invest. 99, 2691-2700 (1997).
21. Soucek, L. et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 13, 1211-1218 (2007).
22. Miller, D. W. et al. Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. Am. J. Pathol. 167, 1389-1403 (2005).
23. Dickson, P. V. et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res. 13, 3942-3950 (2007).
24. Wildiers, H. et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 88, 1979-1986 (2003).
25. Heeschen, C. et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat. Med. 7, 833-839 (2001).
26. Lutzelschwab, C., Huang, M. R., Kullberg, M. C., Aveskogh, M. & Hellman, L. Characterization of mouse mast cell protease-8, the first member of a novel subfamily of mouse mast cell serine proteases, distinct from both the classical chymases and tryptases. Eur. J. Immunol. 28, 1022-1033 (1998).
27. Hendel, A., Hsu, I. & Granville, D. J. Granzyme B releases vascular endothelial growth factor from extracellular matrix and induces vascular permeability. Lab. Invest. 94, 716-725 (2014).
28. Buzza, M. S. et al. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J. Biol. Chem. 280, 23549-23558 (2005).
29. Buzza, M. S. et al. Antihemostatic activity of human granzyme B mediated by cleavage of von Willebrand factor. J. Biol. Chem. 283, 22498-22504 (2008).
30. Schultz, G. S. & Wysocki, A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen. 17, 153-162 (2009).
31. Upton, Z. et al. Vitronectin: growth factor complexes hold potential as a wound therapy approach. J. Invest. Dermatol. 128, 1535-1544 (2008).
32. Qu, Z. et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am. J. Pathol. 147, 564-573 (1995).
33. Kinoshita, M., Miyamoto, T., Ohashi, N., Sasayama, S. & Matsumori, A. Thrombosis increases circulatory hepatocyte growth factor by degranulation of mast cells. Circulation 106, 3133-3138 (2002).
34. Papaetis, G. S. & Syrigos, K. N. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 23, 377-389 (2009).
35. Nigrovic, P. A. et al. Genetic inversion in mast cell-deficient (Wsh) mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. Am. J. Pathol. 173, 1693-1701 (2008).
36. Reber, L. L., Marichal, T. & Galli, S. J. New models for analyzing mast cell functions in vivo. Trends Immunol. 33, 613-625 (2012).
37. Milenkovic, N. et al. Nociceptive tuning by stem cell factor/c-Kit signaling. Neuron 56, 893-906 (2007).
38. Peters, E. M. et al. Kit is expressed by epithelial cells in vivo. J. Invest. Dermatol. 121, 976-984 (2003).
39. Takagi, K. et al. Involvement of stem cell factor and its receptor tyrosine kinase c-kit in pain regulation. Neuroscience 153, 1278-1288 (2008).
40. Pardo, J. et al. Granzyme B is expressed in mouse mast cells in vivo and in vitro and causes delayed cell death independent of perforin. Cell Death Differ. 14, 1768-1779 (2007).
41. Oka, T., Kalesnikoff, J., Starkl, P., Tsai, M. & Galli, S. J. Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice. Lab. Invest. 92, 1472-1482 (2012).
42. Murakami, M. et al. The FGF system has a key role in regulating vascular integrity. J. Clin. Invest. 118, 3355-3366 (2008).
43. Mundhenke, C., Meyer, K., Drew, S. & Friedl, A. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am. J. Pathol. 160, 185-194 (2002).
44. Schulz, M. W., Chamberlain, C. G. & McAvoy, J. W. Binding of FGF-1 and FGF-2 to heparan sulphate proteoglycans of the mammalian lens capsule. Growth Factors 14, 1-13 (1997).
45. Brown, A., Robinson, C. J., Gallagher, J. T. & Blundell, T. L. Cooperative heparin-mediated oligomerization of fibroblast growth factor-1 (FGF1) precedes recruitment of FGFR2 to ternary complexes. Biophys. J. 104, 1720-1730 (2013).
46. Oschatz, C. et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34, 258-268 (2011).
47. Bono, F. et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell. 23, 477-488 (2013).
48. Bussolino, F. et al. In vitro and in vivo activation of endothelial cells by colonystimulating factors. J. Clin. Invest. 87, 986-995 (1991).
49. Marks, R. M., Roche, W. R., Czerniecki, M., Penny, R. & Nelson, D. S. Mast cell granules cause proliferation of human microvascular endothelial cells. Lab. Invest. 55, 289-294 (1986).
50. Compton, S. J., Cairns, J. A., Holgate, S. T. & Walls, A. F. The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for IL-1 beta and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. J. Immunol. 161, 1939-1946 (1998).
51. Mierke, C. T. et al. Human endothelial cells regulate survival and proliferation of human mast cells. J. Exp. Med. 192, 801-811 (2000).
52. Davis, G. E. & Senger, D. R. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 97, 1093-1107 (2005).
53. Thompson, H. L., Burbelo, P. D., Yamada, Y., Kleinman, H. K. & Metcalfe, D. D. Mast cells chemotax to laminin with enhancement after IgE-mediated activation. J. Immunol. 143, 4188-4192 (1989).
54. Samoszuk, M., Kanakubo, E. & Chan, J. K. Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts. BMC Cancer 5, 121 (2005).
55. Shi, Y. et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 16, 126-133 (2006).
56. Facciabene, A., Motz, G. T. & Coukos, G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72, 2162-2171 (2012).
57. Dalton, H. J. et al. Monocyte subpopulations in angiogenesis. Cancer Res. 74, 1287-1293 (2014).
58. Liang, W. & Ferrara, N. The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol. Res. 4, 83-91 (2016).
59. Cheon, E. C. et al. Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice. Cancer Res. 71, 1627-1636 (2011).
60. Ribatti, D. & Ranieri, G. Tryptase, a novel angiogenic factor stored in mast cell granules. Exp. Cell Res. 332, 157-162 (2015).
61. Pejler, G., Ronnberg, E., Waern, I. & Wernersson, S. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 115, 4981-4990 (2010).
62. Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737-744 (2000).
63. Zaitseva, L. et al. Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. Oncotarget 5, 9930-9938 (2014).
64. Juurikivi, A. et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann. Rheum. Dis. 64, 1126-1131 (2005).
65. Cerny-Reiterer, S. et al. Long-term treatment with imatinib results in profound mast cell deficiency in Ph+chronic myeloid leukemia. Oncotarget 6, 3071-3084 (2015).
66. Kalesnikoff, J. & Galli, S. J. Antiinflammatory and immunosuppressive functions of mast cells. Methods Mol. Biol. 677, 207-220 (2011).
67. Weber, K., Bartsch, U., Stocking, C. & Fehse, B. A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol. Ther. 16, 698-706 (2008).
68. Mazzone, M. et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136, 839-851 (2009).
69. Fischer, C. et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463-475 (2007).
70. Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).